RBX7455 Oral Clostridium difficile Prevention

Rebiotix has leveraged its clinical and regulatory experience with RBX2660 to develop the first of its kind non-frozen, room temperature stable oral microbiota-based formulation under the MRT™ drug platform, known as RBX7455. While it is currently used to target recurrent Clostridium difficile infection prevention, additional indications are currently under investigation.

About RBX7455

  • Oral MRT will enable easier application for repeat dosing
  • Lyophilized formulation
  • Room temperature stability
  • Broad spectrum gut microbiota
  • Master File submitted to the U.S. Food and Drug Administration
  • First human clinical study began Q4 2016
RBX7455 Oral Clostridium difficile Prevention Rebiotix